Expert review on global real-world vaccine effectiveness against SARS-CoV-2
Issued Date
2022-01-01
Resource Type
ISSN
14760584
eISSN
17448395
Scopus ID
2-s2.0-85133777621
Pubmed ID
35748494
Journal Title
Expert Review of Vaccines
Volume
21
Issue
9
Start Page
1255
End Page
1268
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Vaccines Vol.21 No.9 (2022) , 1255-1268
Suggested Citation
Chuenkitmongkol S., Solante R., Burhan E., Chariyalertsak S., Chiu N.C., Do-Van D., Husin M., Hwang K.P., Kiertiburanakul S., Kulkarni P.S., Lee P.I., Lobo R.C., Nghia C.H., Ong-Lim A., Sivasampu S., Suah J.L., Tok P.S.K., Thwaites G. Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Review of Vaccines Vol.21 No.9 (2022) , 1255-1268. 1268. doi:10.1080/14760584.2022.2092472 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83897
Title
Expert review on global real-world vaccine effectiveness against SARS-CoV-2
Author's Affiliation
China Medical University Children's Hospital
Oxford University Clinical Research Unit
Pasteur Institute in Ho Chi Minh City
San Lazaro Hospital
Philippine Children's Medical Center
University of the Philippines College of Medicine
University of Medicine and Pharmacy at HCMC
Universitas Indonesia
Mackay Memorial Hospital Taiwan
National Taiwan University College of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Kementerian Kesihatan Malaysia
Nuffield Department of Medicine
Chiang Mai University
Serum Institute of India Ltd.
National Vaccine Institute
Oxford University Clinical Research Unit
Pasteur Institute in Ho Chi Minh City
San Lazaro Hospital
Philippine Children's Medical Center
University of the Philippines College of Medicine
University of Medicine and Pharmacy at HCMC
Universitas Indonesia
Mackay Memorial Hospital Taiwan
National Taiwan University College of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Kementerian Kesihatan Malaysia
Nuffield Department of Medicine
Chiang Mai University
Serum Institute of India Ltd.
National Vaccine Institute
Other Contributor(s)
Abstract
Introduction: COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. While primary series vaccination rates are generally high in Southeast Asian (SEA) countries, various factors have limited the rollout and impact of booster doses. Areas covered: We reviewed 79 studies in the International Vaccine Access Center (IVAC) VIEW-hub platform on vaccine effectiveness (VE) after primary immunizations with two-dose schedules. VE data were reported for SARS-CoV-2 infection, COVID-19-related hospitalizations and deaths, and stratified across variants of concern, age, study design and prior SARS-CoV-2 infection for mRNA vaccines (BNT162b2, mRNA-1273, and combinations of both), vector vaccines (AstraZeneca, AZD1222 [ChAdOx1 nCoV-19] ‘Vaxzevria’), and inactivated virus vaccines (CoronaVac). Expert opinion: The most-studied COVID-19 vaccines provide consistently high (>90%) protection against serious clinical outcomes like hospitalizations and deaths, regardless of variant. Additionally, this protection appears equivalent for mRNA vaccines and vector vaccines like AZD1222, as supported by our analysis of Asian and relevant international data, and by insights from SEA experts. Given the continued impact of COVID-19 hospitalizations and deaths on health-care systems worldwide, encouraging vaccination strategies that reduce this burden is more relevant than attempting to prevent broader but milder infections with specific variants, including Omicron.